Literature DB >> 26783419

Chaperones in hepatitis C virus infection.

Ronik Khachatoorian1, Samuel W French1.   

Abstract

The hepatitis C virus (HCV) infects approximately 3% of the world population or more than 185 million people worldwide. Each year, an estimated 350000-500000 deaths occur worldwide due to HCV-associated diseases including cirrhosis and hepatocellular carcinoma. HCV is the most common indication for liver transplantation in patients with cirrhosis worldwide. HCV is an enveloped RNA virus classified in the genus Hepacivirus in the Flaviviridae family. The HCV viral life cycle in a cell can be divided into six phases: (1) binding and internalization; (2) cytoplasmic release and uncoating; (3) viral polyprotein translation and processing; (4) RNA genome replication; (5) encapsidation (packaging) and assembly; and (6) virus morphogenesis (maturation) and secretion. Many host factors are involved in the HCV life cycle. Chaperones are an important group of host cytoprotective molecules that coordinate numerous cellular processes including protein folding, multimeric protein assembly, protein trafficking, and protein degradation. All phases of the viral life cycle require chaperone activity and the interaction of viral proteins with chaperones. This review will present our current knowledge and understanding of the role of chaperones in the HCV life cycle. Analysis of chaperones in HCV infection will provide further insights into viral/host interactions and potential therapeutic targets for both HCV and other viruses.

Entities:  

Keywords:  Chaperones; Heat shock proteins; Hepatitis C; Hepatitis C virus; Viral life cycle

Year:  2016        PMID: 26783419      PMCID: PMC4705456          DOI: 10.4254/wjh.v8.i1.9

Source DB:  PubMed          Journal:  World J Hepatol


  325 in total

1.  Mutant Ninja viruses.

Authors:  Graham R Foster
Journal:  Hepatology       Date:  2015-01-05       Impact factor: 17.425

2.  Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease.

Authors:  K Inoue; M Yoshiba
Journal:  Transplant Proc       Date:  2005-03       Impact factor: 1.066

3.  Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.

Authors:  Koichi Watashi; Naoto Ishii; Makoto Hijikata; Daisuke Inoue; Takayuki Murata; Yusuke Miyanari; Kunitada Shimotohno
Journal:  Mol Cell       Date:  2005-07-01       Impact factor: 17.970

4.  HSC90 is required for nascent hepatitis C virus core protein stability in yeast cells.

Authors:  Naoko Kubota; Yasutaka Inayoshi; Naoko Satoh; Takashi Fukuda; Kenta Iwai; Hiroshi Tomoda; Michinori Kohara; Kazuhiro Kataoka; Akira Shimamoto; Yasuhiro Furuichi; Akio Nomoto; Akira Naganuma; Shusuke Kuge
Journal:  FEBS Lett       Date:  2012-05-31       Impact factor: 4.124

5.  Cytoskeletal requirements for hepatitis C virus (HCV) RNA synthesis in the HCV replicon cell culture system.

Authors:  Anne G Bost; Daryl Venable; Lifei Liu; Beverly A Heinz
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin.

Authors:  Yaakov Nahmias; Jonathan Goldwasser; Monica Casali; Daan van Poll; Takaji Wakita; Raymond T Chung; Martin L Yarmush
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

7.  Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner.

Authors:  Toshana L Foster; Philippe Gallay; Nicola J Stonehouse; Mark Harris
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

8.  A cell-permeable hairpin peptide inhibits hepatitis C viral nonstructural protein 5A-mediated translation and virus production.

Authors:  Ronik Khachatoorian; Vaithilingaraja Arumugaswami; Piotr Ruchala; Santanu Raychaudhuri; Eden M Maloney; Edna Miao; Asim Dasgupta; Samuel W French
Journal:  Hepatology       Date:  2012-01-30       Impact factor: 17.425

9.  Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro.

Authors:  John M Robida; Heather B Nelson; Zhe Liu; Hengli Tang
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

10.  Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A.

Authors:  Claire Rosnoblet; Bernd Fritzinger; Dominique Legrand; Hélène Launay; Jean-Michel Wieruszeski; Guy Lippens; Xavier Hanoulle
Journal:  J Biol Chem       Date:  2012-11-14       Impact factor: 5.157

View more
  6 in total

Review 1.  Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.

Authors:  Qianya Wan; Dan Song; Huangcan Li; Ming-Liang He
Journal:  Signal Transduct Target Ther       Date:  2020-07-13

2.  The Dengue Virus Nonstructural Protein 1 (NS1) Is Secreted from Mosquito Cells in Association with the Intracellular Cholesterol Transporter Chaperone Caveolin Complex.

Authors:  Romel Rosales Ramirez; Juan E Ludert
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

3.  Perturbation of Wound Healing, Cytoskeletal Organization and Cellular Protein Networks during Hazara Virus Infection.

Authors:  Andrea Molinas; Maria V Turkina; Karl-Eric Magnusson; Ali Mirazimi; Elena Vikström
Journal:  Front Cell Dev Biol       Date:  2017-11-21

4.  Heat shock proteins HSPB8 and DNAJC5B have HCV antiviral activity.

Authors:  Ana Claudia Silva Braga; Bruno Moreira Carneiro; Mariana Nogueira Batista; Mônica Mayumi Akinaga; Cíntia Bittar; Paula Rahal
Journal:  PLoS One       Date:  2017-11-28       Impact factor: 3.240

Review 5.  Diversity in heat shock protein families: functional implications in virus infection with a comprehensive insight of their role in the HIV-1 life cycle.

Authors:  Kruthika Iyer; Kailash Chand; Alapani Mitra; Jay Trivedi; Debashis Mitra
Journal:  Cell Stress Chaperones       Date:  2021-07-27       Impact factor: 3.667

Review 6.  Heat shock proteins and viral infection.

Authors:  Xizhen Zhang; Wei Yu
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.